Out-licensing

We have technology to produce chiral intermediates of high quality by biotransformation

Chiral intermediates are produced from prochiral or racemic compounds using biocatalysts

Chirotechnology is an indispensable technoogy for manufacturing chiral pharmaceutical intermediates. Chirotechnology continues to have broad applications for the global drugs industry as about 80% of the drugs in development are single-isomer products, according to a new report by Frost & Sullivan 2003 Report. The report calculates the global chiral intermediates market to be worth $7.00 billion in 2002 and expects this to grow to $14.9 billion by 2009 There are four main technologies used by the chiral industry to manufacture chiral intermediates (fermentation, classical resolution, biotransformation, asymmetric synthesis).

The numbers of products produced by fermentation are decreasing, the numbers produced by synthesis, biotransformation and asymmetric synthesis are increasing. Asymmetric synthesis has disadvantages such as: - high price of chiral metal catalyst - lower optical purity comparing to those produced by biotransformation Biotransformation uses enzymes to catalyze the structural modification of a molecule.

The use of enzymes means that this type of technology gives the complete enantiomer. Biocatalysis is able to combine low costs with high optical purity. At EnzyTech, Ltd., we have exclusive technology to produce chiral intermediates. This technology has been developed to isolate or synthesize the chiral intermediates using enzymes. It is possible to produce chiral intermediates of higher quality and lower cost compared with those produced by other technologies.

Optical purity is over 99%, chemical purity is 98%. Market potential--Trend of chiral switch The chiral intermediates market is changing due to regulatory changes and the demand for single enantiomers. Most drugs were sold as racemates. The current move to single enantiomeric drugs received a push in 1992 when the FDA issued a policy statement. In the future, more than 60% drugs will be sold as single enantiomeric drugs. Demand for chiral intermediates will increase due to the increasing market for chiral drugs.

Early Stage

Twelve patents were registered and twenty-one patents were applied. Among them six patents were applied to PCT. - PCT/KR2004/000211, - PCT/KR2004/001005, - PCT/KR2004/001313, - PCT/KR2005/001213 - PCT/KR2006/002002, - PCT/KR2006/002003

- Investment - Licensing out